Navigation Links
Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis
Date:7/5/2009

well as in contact lens care solutions. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay(R) and Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit: www.novabaypharma.com.

Forward-Looking Statements

The statements in this press release regarding NovaBay's and Alcon's expectations regarding the clinical trial and the potential efficacy of Aganocide(R) compounds are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward- looking statements reflect the views of the management of NovaBay and Alcon as of the date of this press release with respect to future events and are based on assumptions and subject to significant risks and uncertainties (many of which are outside of NovaBay's or Alcon's control), including the risk that FDA or other regulatory review may delay or prevent the development of Aganocide(R) compounds, and those detailed in the NovaBay's and Alcon's filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.; Alcon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ORBIS and Alcon Call Attention to the Aging Eye
2. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
3. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
4. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
5. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
6. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Cytopia Commences Second Phase II Study in Brain Cancer
10. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
11. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  Over 100 million adults suffer from chronic ... pain daily. Chronic and acute pain dramatically impacts quality ... to fulfill the need for non-surgical, interventional solutions and ... On October 28th, a new pain management center ... community.  This new facility boasts cutting edge ...
(Date:11/26/2014)... 26, 2014 Zynerba Pharmaceuticals , Inc., ... innovative transdermal synthetic cannabinoid treatments, today announced that the ... Healthcare Conference 2014. The conference will be held December ... New York . Zynerba,s Chairman and ... pm on Tuesday, December 2. To listen ...
(Date:11/26/2014)... -- According to the new research ... Battery, Pneumatic), by Product (Drill, Saw, Stapler, Reamer, ... (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global Forecasts ... Instruments Market is estimated to be worth around ... expected to grow at a moderate CAGR during ...
Breaking Medicine Technology:New Pain Management Center Opens in Cumberland, Md. 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4
... GRONINGEN, Netherlands , July 26 ... organization providing testing services to support preclinical and clinical ... of Xendo Drug Development BV (XDD), headquartered in Groningen, ... organization (CRO), will be known as QPS Netherlands BV ...
... Harco Metal Products (Harco), an industry leader in tube ... contract to manufacture MediGLIDER™ products for ConMediSys. , ... ConMediSys, the developer of safety products ... risk and cost associated with staff injuries caused by physically lifting ...
Cached Medicine Technology:QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2
(Date:11/27/2014)... 2014 This is a professional and ... Bronchoscopes industry with a focus on the Chinese market. ... of the Bronchoscopes manufacturers and is a valuable source ... in the industry. , Firstly, the report provides a ... and manufacturing technology. Then, the report explores the international ...
(Date:11/27/2014)... The American Society for Clinical Pathology (ASCP) announced ... honor of World AIDS Day 2014. On Nov. 25, ASCP ... icon and infographic designed to generate public awareness about World ... , ASCP has asked members to replace their Facebook, Twitter, ... Tested. Find a cure.” icon and share the accompanying infographic ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 According to ... those companies looking to break into the surgical ... medical specialties, other than the MIS field dominated by ... of the U.S. surgical robotics market by 2020. ... explains Dr. Kamran Zamanian, CEO and President of iData. ...
(Date:11/27/2014)... 27, 2014 In a world ... to sleep has lessened, and due to the ... quality of sleep has eroded. According to Web ... the job (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This remarkably ... by an incalculable amount, leading not only to ...
(Date:11/27/2014)... 27, 2014 "As a nurse I ... effects of urinary incontinence," said an inventor from Whiting, ... this specialized accessory to prevent leakage and keep them ... absorb urine leakage. This prevents stains on pants, skirts ... The pad ensures that the individual has time to ...
Breaking Medicine News(10 mins):Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3Health News:ASCP Launches Social Media Campaign in Honor of World AIDS Day 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2
... The following was released today by the Center to Expose ... to Expose and Close Animal Factories (CECAF) will hold a ... caused by animal "factories." Among the topics will be ... in Veracruz, Mexico. Officials in Mexico are looking at ...
... product designer to open industry,s best-attended and most ... Orlando, Florida, October 31 - November 3, 2009. ... of HEALTHCARE DESIGN magazine, and The ... education, and advocacy organization, today announced that architect ...
... The New Investigator Career Highlight Forum at the ninth ... 4, 2009 at the John B. Hynes Convention Center ... innovative research in transplantation. These promising investigators have ... Surgeons (ASTS) or the American Society of Transplantation (AST). ...
... 29 Millennium Dental Technologies, Inc. has issued ... statement on the use of lasers in dentistry. ... misleading, and scientifically unsubstantiated, especially as it relates ... protocol. http://www.ada.org/prof/resources/positions/statements/lasers_final.asp ...
... reading disabilities , , WEDNESDAY, April 29 (HealthDay News) -- ... located in the brain,s visual word form area, U.S. ... 30 issue of Neuron , offers new insight ... of reading disabilities. , "Although some theories of reading, ...
... immunotherapy for the treatment of allergy symptoms caused by ... used in Europe. It should be employed to further ... symptoms are largely undertreated, according to an invited article ... Neck Surgery . A response to the article, published ...
Cached Medicine News:Health News:Celebrated Architect Michael Graves to Keynote HEALTHCARE DESIGN.09 Conference 2Health News:Celebrated Architect Michael Graves to Keynote HEALTHCARE DESIGN.09 Conference 3Health News:Celebrated Architect Michael Graves to Keynote HEALTHCARE DESIGN.09 Conference 4Health News:American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research 2Health News:LANAP Inventors Call ADA's Laser Position Statement Flawed 2Health News:LANAP Inventors Call ADA's Laser Position Statement Flawed 3Health News:LANAP Inventors Call ADA's Laser Position Statement Flawed 4Health News:Imaging IDs Brain Neurons With Preference for Real Words 2Health News:Sublingual immunotherapy for inhalant allergies deserves deeper consideration 2